116 related articles for article (PubMed ID: 25525464)
1. T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept.
Ingels A; Sanchez Salas RE; Ravery V; Fromont-Hankard G; Validire P; Patard JJ; Pignot G; Prapotnich D; Olivier F; Galiano M; Barret E; Rozet F; Weber N; Cathelineau X
Ecancermedicalscience; 2014; 8():486. PubMed ID: 25525464
[TBL] [Abstract][Full Text] [Related]
2. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
Yu A; Mansure JJ; Solanki S; Siemens DR; Koti M; Dias ABT; Burnier MM; Brimo F; Kassouf W
PLoS One; 2018; 13(10):e0205746. PubMed ID: 30308033
[TBL] [Abstract][Full Text] [Related]
3. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
[TBL] [Abstract][Full Text] [Related]
4. Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study.
Bieri U; Enderlin D; Buser L; Wettstein MS; Eberli D; Moch H; Hermanns T; Poyet C
Front Oncol; 2022; 12():964672. PubMed ID: 36212478
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
6. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.
Rouanne M; Betari R; Radulescu C; Goubar A; Signolle N; Neuzillet Y; Allory Y; Marabelle A; Adam J; Lebret T
Eur J Cancer; 2019 Feb; 108():111-119. PubMed ID: 30654296
[TBL] [Abstract][Full Text] [Related]
7. High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer.
Shi MJ; Meng XY; Wu QJ; Zhou XH
Cancer Manag Res; 2019; 11():2987-2995. PubMed ID: 31114346
[No Abstract] [Full Text] [Related]
8. Prognostic significance of tumor-infiltrating immune cells in muscle-invasive bladder cancer.
Peng YL; Wu ZS; Lu HM; Wei WS; Xiong LB; Yu CP; Liu ZF; Li XD; Jiang LJ; Li YH; Liu ZW; Zhang ZL; Zhou FJ
Am J Transl Res; 2020; 12(10):6524-6536. PubMed ID: 33194049
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
[TBL] [Abstract][Full Text] [Related]
10. Density and location of CD3
Zhou C; Wu Y; Jiang L; Li Z; Diao P; Wang D; Zhang W; Liu L; Wang Y; Jiang H; Cheng J; Yang J
J Oral Pathol Med; 2018 Apr; 47(4):359-367. PubMed ID: 29469989
[TBL] [Abstract][Full Text] [Related]
11. Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens.
Murai R; Itoh Y; Kageyama S; Nakayama M; Ishigaki H; Teramoto K; Narita M; Yoshida T; Tomita K; Kobayashi KI; Wada A; Nagasawa M; Kubota S; Ogasawara K; Kawauchi A
PLoS One; 2018; 13(9):e0204745. PubMed ID: 30261082
[TBL] [Abstract][Full Text] [Related]
12. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma.
Krpina K; Babarović E; Jonjić N
Virchows Arch; 2015 Oct; 467(4):443-8. PubMed ID: 26215559
[TBL] [Abstract][Full Text] [Related]
13. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
[TBL] [Abstract][Full Text] [Related]
15. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
17. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
18. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
Kamiya N; Suzuki H; Suyama T; Kobayashi M; Fukasawa S; Sekita N; Mikami K; Nihei N; Naya Y; Ichikawa T
Int J Clin Oncol; 2017 Apr; 22(2):353-358. PubMed ID: 27744487
[TBL] [Abstract][Full Text] [Related]
20. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
